Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target

A technology for therapeutic targets and side effects, applied in drug combinations, medical preparations containing active ingredients, anti-tumor drugs, etc., can solve problems such as large side effects that are difficult to suppress

Active Publication Date: 2020-01-10
THE SECOND HOSPITAL OF SHANDONG UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The present invention proposes a novel side effect suppression or therapeutic target of cisplatin drugs aiming at the problem that the side effects existing in the traditional cancer treatment process are too large and difficult to suppress

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target
  • Cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target
  • Cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] LncRNA-MEG3 targets miR-126 to regulate the effect of PI3K / AKT / mTOR signaling pathway on autophagy

[0056] 1. Expression of MEG3 in cisplatin nephrotoxicity

[0057] HK-2 and TCMK-1 renal tubular epithelial cells were selected, treated with cisplatin (20, 40, 60 μM) for 24 h or 40 μM cisplatin for 12, 24 and 48 h, and the expression of MEG3 in the cells was detected by RT-PCR. Expression; C57BL / 6 normal / lung cancer mice, after 3 days of cisplatin (10, 20, 30 mg / kg) or 20 mg / kg cisplatin for 1, 3, 5 days, RT-PCR detection of mouse kidney tissue Expression of MEG3 in . see attached results figure 1 .

[0058] 2. MEG3 inhibits autophagy in renal tubular epithelial cells

[0059] 2.1 In the gene knockout or gene silencing system, detect the effect of MEG3 deletion on autophagy

[0060] 1) siRNA or shRNA transfection of HK-2 cell line to silence MEG3: HK-2 cells with good growth status were selected and randomly divided into normal control group, siRNA or shRNA MEG3 gr...

Embodiment 2

[0086] In vitro experiment of paeonol regulating autophagy mediated by LncRNA-MEG3 / miR-126 / mTOR signaling pathway on cisplatin nephrotoxicity

[0087] 1. Establishment and grouping of cisplatin nephrotoxicity cell model

[0088] Renal tubular epithelial cells HK-2 and TCMK-1 cell lines were treated with 40 μM cisplatin for 24 h and divided into three groups: negative control group, MEG3 silencing group and paeonol (40 μM) intervention group.

[0089] 2. The protective effect of paeonol on renal tubular epithelial cell injury ( Figure 5-Figure 7 )

[0090] MTT and CCK-8 were used to detect cell proliferation; flow cytometry and TUNEL were used to detect cell apoptosis; Western blot and immunofluorescence were used to detect the expression of apoptosis-related proteins (P53, Bax, Bcl-2 and caspase-3); ELISA Changes of inflammatory factors (IL-2, IL-6, TNF-α, IFN-γ) were detected. Rapamycin was added to induce autophagy or 3MA to block autophagy to observe the protective effe...

Embodiment 3

[0096] Paeonol regulates autophagy mediated by LncRNA-MEG3 / miR-126 / mTOR signaling pathway on the mechanism of cisplatin nephrotoxicity in vivo

[0097] 1. Establishment of an animal model of cisplatin nephrotoxicity

[0098] Lewis lung cancer cells were cultured, tumor cells in the logarithmic growth phase were collected, the concentration of the cell suspension was adjusted to 1×107 / mL, and 0.2 mL of the cell suspension was subcutaneously injected into the right axilla of C57BL / 6 mice to establish Lewis lung cancer mice subcutaneously. Xenograft tumor animal model. On the 8th day after inoculation (the tumor volume is about 8mm), the normal mice were administered at the same time: one-time intraperitoneal injection of 20 mg / kg cisplatin, one group was the negative control group, and the other group was intragastrically administered paeonol (30 mg / kg) every day. mg / kg), for 3 consecutive days. On the fourth day, the mice were sacrificed after taking heart blood and kidney ti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of side effect inhibition of cancer drug treatment, and relates to a cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target.According to the cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target, aiming at the problem of kidney injury in the course of cancer treatment, an LncRNA matrilineal expression gene 3 is provided as a treatment target of the kidney injury, the inhibitory effect of paeonol on the LncRNA matriarchal expression gene 3 is further provided, and a novel idea is providedfor side effect inhibition in the course of cancer treatment.

Description

technical field [0001] The invention belongs to the technical field of suppressing side effects of cancer drug treatment, and relates to a side effect suppressing or therapeutic target of cisplatin drugs. Background technique [0002] Cisplatin (Cis-dischlorodiammine-platinum, CDDP), as a metal platinum complex, is a dose-dependent chemotherapeutic drug, and its anti-tumor effect is positively correlated with its drug dose. At present, cisplatin is recommended as one of the first-choice drugs for cancer treatment in the United States and Canada. In my country, cisplatin-based or cisplatin-involved chemotherapy regimens account for 70-80%. The therapeutic effect of cisplatin on malignant tumors makes its The status is currently irreplaceable. However, the main accumulation organ of cisplatin in the human body is the kidney, which can cause cumulative toxic damage and cause irreversible damage to the kidney. About 1 / 3 of tumor patients receiving high-dose cisplatin therapy de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/12A61P35/00A61P13/12C12Q1/6883
CPCA61K31/12A61K45/00A61P13/12A61P35/00C12Q1/6883C12Q2600/106C12Q2600/158C12Q2600/178
Inventor 武静靖旭郑惠延王道清鲍志国王亚军
Owner THE SECOND HOSPITAL OF SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com